Patents by Inventor Susan K. Paulson

Susan K. Paulson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20190211093
    Abstract: The invention provides a liquid aqueous pharmaceutical formulation comprising a human anti-TNFa antibody, or antigen-binding portion thereof, which reduces pain associated with injection in a subject by at least about 50% when compared to injecting an otherwise identical formulation comprising at least one salt and/or at least one buffer. The invention also provides a liquid aqueous pharmaceutical formulation comprising a human anti-TNFa antibody, or antigen-binding portion thereof, having increased bioavailability upon subcutaneous administration into a subject. The formulation may comprise a therapeutic protein, such as a human anti-TNF-alpha antibody, or an antigen-binding portion thereof, or a biosimilar thereof.
    Type: Application
    Filed: August 10, 2018
    Publication date: July 11, 2019
    Inventors: Michael Neu, Markus Tschoepe, Carsten Weber, Wolfgang Fraunhofer, Laura Redden, Martin Gastens, Alexander Feick, Susan K. Paulson, Tong Zhu
  • Publication number: 20190055308
    Abstract: Multiple-variable dose methods for treating TNFa-related disorders, including Crohn's disease and psoriasis, comprising administering TNFa inhibitors, including TNFa antibodies, are described. Multiple-variable dose methods include administration of a TNF-inhibitor in an induction or loading phase followed by administration of the agent in a maintenance or treatment phase, wherein the TNF-inhibitor is administered in a higher dosage during the induction phase.
    Type: Application
    Filed: March 8, 2018
    Publication date: February 21, 2019
    Inventors: Rebecca S. Hoffman, Elliot Keith Chartash, Lori K. Taylor, George Richard Granneman, Philip Yan, Susan K. Paulson, Joanna Z. Peng
  • Publication number: 20180110854
    Abstract: The invention provides methods and compositions for the treatment of juvenile idiopathic arthritis (JIA) where a TNF? inhibitor, such as a human TNF? antibody, or antigen-binding portion thereof, is used to treat JIA. In particular, the invention is directed to methods and compositions relating to a fixed dosing regimen for treating JIA with a TNF? inhibitor.
    Type: Application
    Filed: June 5, 2017
    Publication date: April 26, 2018
    Inventors: John R. Medich, Susan K. Paulson, Peter A. Noertersheuser
  • Patent number: 9669093
    Abstract: The invention provides methods and compositions for the treatment of juvenile idiopathic arthritis (JIA) where a TNF? inhibitor, such as a human TNF? antibody, or antigen-binding portion thereof, is used to treat JIA. In particular, the invention is directed to methods and compositions relating to a fixed dosing regimen for treating JIA with a TNF? inhibitor.
    Type: Grant
    Filed: February 12, 2016
    Date of Patent: June 6, 2017
    Assignee: AbbVie Biotechnology Ltd
    Inventors: John R. Medich, Susan K. Paulson, Peter A. Noertersheuser
  • Publication number: 20170044249
    Abstract: Multiple-variable dose methods for treating TNF?-related disorders, including Crohn's disease and psoriasis, comprising administering TNF? inhibitors, including TNF? antibodies, are described. Multiple-variable dose methods include administration of a TNF-inhibitor in an induction or loading phase followed by administration of the agent in a maintenance or treatment phase, wherein the TNF-inhibitor is administered in a higher dosage during the induction phase.
    Type: Application
    Filed: June 19, 2015
    Publication date: February 16, 2017
    Inventors: Rebecca S. Hoffman, Elliot Keith Chartash, Lori K. Taylor, George Richard Granneman, Philip Yan, Susan K Paulson, Joanna Z. Peng
  • Publication number: 20160151488
    Abstract: The invention provides methods and compositions for the treatment of juvenile idiopathic arthritis (JIA) where a TNF? inhibitor, such as a human TNF? antibody, or antigen-binding portion thereof, is used to treat JIA. In particular, the invention is directed to methods and compositions relating to a fixed dosing regimen for treating JIA with a TNF? inhibitor.
    Type: Application
    Filed: February 12, 2016
    Publication date: June 2, 2016
    Inventors: John R. Medich, Susan K. Paulson, Peter A. Noertersheuser
  • Patent number: 9284370
    Abstract: The invention provides methods and compositions for the treatment of juvenile idiopathic arthritis (JIA) where a TNF? inhibitor, such as a human TNF? antibody, or antigen-binding portion thereof, is used to treat JIA. In particular, the invention is directed to methods and compositions relating to a fixed dosing regimen for treating JIA with a TNF? inhibitor.
    Type: Grant
    Filed: April 6, 2015
    Date of Patent: March 15, 2016
    Assignee: AbbVie Biotechnology Ltd.
    Inventors: John R. Medich, Susan K. Paulson, Peter A. Noertersheuser
  • Publication number: 20160060336
    Abstract: The invention provides methods and compositions for the treatment of juvenile idiopathic arthritis (JIA) where a TNF? inhibitor, such as a human TNF? antibody, or antigen-binding portion thereof, is used to treat JIA. In particular, the invention is directed to methods and compositions relating to a fixed dosing regimen for treating JIA with a TNF? inhibitor.
    Type: Application
    Filed: April 6, 2015
    Publication date: March 3, 2016
    Inventors: John R. Medich, Susan K. Paulson, Peter A. Noertersheuser
  • Publication number: 20160017030
    Abstract: The invention provides a liquid aqueous pharmaceutical formulation comprising a human anti-TNFa antibody, or antigen-binding portion thereof, which reduces pain associated with injection in a subject by at least about 50% when compared to injecting an otherwise identical formulation comprising at least one salt and/or at least one buffer. The invention also provides a liquid aqueous pharmaceutical formulation comprising a human anti-TNFa antibody, or antigen-binding portion thereof, having increased bioavailability upon subcutaneous administration into a subject. The formulation may comprise a therapeutic protein, such as a human anti-TNF-alpha antibody, or an antigen-binding portion thereof, or a biosimilar thereof.
    Type: Application
    Filed: July 30, 2015
    Publication date: January 21, 2016
    Inventors: Michael Neu, Markus Tschoepe, Carsten Weber, Wolfgang Fraunhofer, Laura Redden, Martin Gastens, Alexander Feick, Susan K. Paulson, Tong Zhu
  • Patent number: 9051368
    Abstract: The invention provides a method of treating psoriasis in a subject by administering to a subject an antibody capable of binding to the p40 subunit of IL-12 and/or IL-23.
    Type: Grant
    Filed: June 10, 2010
    Date of Patent: June 9, 2015
    Assignee: AbbVie, Inc.
    Inventors: Elliot Keith Chartash, William T. Barchuk, Susan K. Paulson, Joaquin M. Valdes, Alexandra B. Kimball
  • Patent number: 8999337
    Abstract: The invention provides methods and compositions for the treatment of juvenile idiopathic arthritis (JIA) where a TNF? inhibitor, such as a human TNF? antibody, or antigen-binding portion thereof, is used to treat JIA. In particular, the invention is directed to methods and compositions relating to a fixed dosing regimen for treating JIA with a TNF? inhibitor.
    Type: Grant
    Filed: June 10, 2008
    Date of Patent: April 7, 2015
    Assignee: AbbVie Biotechnology Ltd.
    Inventors: John R. Medich, Susan K. Paulson, Peter A. Noertersheuser
  • Patent number: 8945545
    Abstract: The invention provides a method of treating psoriasis in a subject by administering to a subject an antibody capable of binding to the p40 subunit of IL-12 and/or IL-23.
    Type: Grant
    Filed: March 8, 2012
    Date of Patent: February 3, 2015
    Assignee: AbbVie Inc.
    Inventors: Joaquin Mario Valdes, Susan K. Paulson
  • Publication number: 20140377275
    Abstract: The invention provides a liquid aqueous pharmaceutical formulation comprising a human anti-TNFa antibody, or antigen-binding portion thereof, which reduces pain associated with injection in a subject by at least about 50% when compared to injecting an otherwise identical formulation comprising at least one salt and/or at least one buffer. The invention also provides a liquid aqueous pharmaceutical formulation comprising a human anti-TNFa antibody, or antigen-binding portion thereof, having increased bioavailability upon subcutaneous administration into a subject. The formulation may comprise a therapeutic protein, such as a human anti-TNF-alpha antibody, or an antigen-binding portion thereof, or a biosimilar thereof.
    Type: Application
    Filed: August 29, 2014
    Publication date: December 25, 2014
    Inventors: Michael Neu, Markus Tschoepe, Carsten Weber, Wolfgang Fraunhofer, Laura Redden, Martin Gastens, Alexander Feick, Susan K. Paulson, Tong Zhu
  • Publication number: 20140093516
    Abstract: The invention provides human antibodies that bind to the p40 subunit of human IL-12 and/or IL-23. The invention further provides a method of treating psoriasis in a subject by administering to a subject an antibody that binds to the p40 subunit of IL-12 and/or IL-23.
    Type: Application
    Filed: October 2, 2013
    Publication date: April 3, 2014
    Inventors: Matthew Hruska, Susan K. Paulson, Peter Noertersheuser, Sven Mensing, Walid Awni
  • Publication number: 20140079714
    Abstract: The invention provides methods of treating psoriasis in a subject by administering to a subject an antibody capable of binding to the p40 subunit of IL-12 and/or IL-23.
    Type: Application
    Filed: September 11, 2013
    Publication date: March 20, 2014
    Inventors: Joaquin Mario Valdes, Elliot K. Chartash, William T. Barchuk, Susan K. Paulson, Kenneth B. Gordon, Walid M. Awni, Yanjun Bao, William G. Glass, Yihua Gu, Thomas C. Harris, Martin Kaul, Parvez M. Mulani, Peter A. Noertersheuser, Martin M. Okun
  • Patent number: 8557239
    Abstract: The invention provides methods of treating psoriasis in a subject by administering to a subject an antibody capable of binding to the p40 subunit of IL-12 and/or IL-23.
    Type: Grant
    Filed: September 14, 2010
    Date of Patent: October 15, 2013
    Assignees: AbbVie Inc., AbbVie Deutschland GmbH & Co. KG
    Inventors: Joaquin Mario Valdes, Elliot K. Chartash, William T. Barchuk, Susan K. Paulson, Kenneth B. Gordon, Walid M. Awni, Yanjun Bao, William G. Glass, Yihua Gu, Tom C. Harris, Martin Kaul, Parvez M. Mulani, Peter Noertersheuser, Martin M. Okun
  • Publication number: 20130122011
    Abstract: Multiple-variable dose methods for treating TNF?-related disorders, including Crohn's disease and psoriasis, comprising administering TNF? inhibitors, including TNF? antibodies, are described. Multiple-variable dose methods include administration of a TNF-inhibitor in an induction or loading phase followed by administration of the agent in a maintenance or treatment phase, wherein the TNF-inhibitor is administered in a higher dosage during the induction phase.
    Type: Application
    Filed: March 28, 2012
    Publication date: May 16, 2013
    Inventors: Rebecca S. Hoffman, Elliot K. Chartash, Lori K. Taylor, George R. Granneman, Philip Yan, Susan K. Paulson, Joanna Z. Peng
  • Publication number: 20120263731
    Abstract: The invention provides a liquid aqueous pharmaceutical formulation comprising a human anti-TNFa antibody, or antigen-binding portion thereof, which reduces pain associated with injection in a subject by at least about 50% when compared to injecting an otherwise identical formulation comprising at least one salt and/or at least one buffer. The invention also provides a liquid aqueous pharmaceutical formulation comprising a human anti-TNFa antibody, or antigen-binding portion thereof, having increased bioavailability upon subcutaneous administration into a subject. The formulation may comprise a therapeutic protein, such as a human anti-TNF-alpha antibody, or an antigen-binding portion thereof, or a biosimilar thereof.
    Type: Application
    Filed: November 11, 2011
    Publication date: October 18, 2012
    Applicant: ABBOTT BIOTECHNOLOGY LTD.
    Inventors: Wolfgang Fraunhofer, Laura Redden, Susan K. Paulson, Tong Zhu, Michael Neu, Markus Tschoepe, Carsten Weber, Martin Gastens, Alexander Feick
  • Publication number: 20120225080
    Abstract: The invention provides human antibodies that bind to the p40 subunit of human IL-12 and/or IL-23. The invention further provides a method of treating psoriasis in a subject by administering to a subject an antibody that binds to the p40 subunit of IL-12 and/or IL-23.
    Type: Application
    Filed: January 13, 2012
    Publication date: September 6, 2012
    Applicant: Abbott Laboratories
    Inventors: Matthew W. Hruska, Susan K. Paulson, Walid Awni, Peter Noertersheuser, Sven Mensing
  • Publication number: 20120219562
    Abstract: The invention provides a method of treating psoriasis in a subject by administering to a subject an antibody capable of binding to the p40 subunit of IL-12 and/or IL-23.
    Type: Application
    Filed: March 8, 2012
    Publication date: August 30, 2012
    Applicant: Abbott Laboratories
    Inventors: Joaquin Mario Valdes, Susan K. Paulson